Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 10:12:70-79.
doi: 10.33393/grhta.2025.3458. eCollection 2025 Jan-Dec.

Costo per responder di upadacitinib 30 mg e di dupilumab 300 mg nel trattamento di pazienti con dermatite atopica moderata-grave in Italia

[Article in Italian]
Luca Stingeni  1 , Roberto Ravasio  2 , Chiara Palladino  3 , Sara Di Fino  3 , Anna Levi  3 , Gianluca Ronci  3 , Paolo Gisondi  4
Affiliations

Costo per responder di upadacitinib 30 mg e di dupilumab 300 mg nel trattamento di pazienti con dermatite atopica moderata-grave in Italia

[Article in Italian]
Luca Stingeni et al. Glob Reg Health Technol Assess. .

Abstract

Purpose:: The objective of this economic evaluation was to compare the cost per responder between upadacitinib (Upa) 30 mg and dupilumab (Dup) 300 mg in patients with moderate-to-severe atopic dermatitis in Italy.

Methods:: A cost per responder analysis was developed based on results of Heads Up, a head-to-head randomized clinical trial. The primary endpoint was EASI75 at week 16, and the secondary endpoints were EASI90, EASI100, and WP-NRS improvement ≥4 points at week 16. The analysis also assessed a fifth exploratory endpoint from a Heads Up post-hoc analysis: EASI90 & WP-NRS 0/1 at week 16. The cost per responder was based on the perspective of the Italian National Health System (I-NHS). Ex-factory prices were used, excluding mandatory and other hidden discounts. The treatment cost was based on the number of administrations at week 16. The cost per responder was adopted as a cost-effectiveness indicator.

Results:: Independently of the endpoint evaluated, upadacitinib always had the lower cost per responder than dupilumab. In the base case, the cost-effectiveness of upadacitinib ranges from a minimum of €361.50 considering EASI75 index at week 16 (Upa: €8,839.78 vs. Dup: €9,201.28) to a maximum of €50,376.18 considering EASI100 index at week 16 (Upa: €22,535.2 vs. Dup: €72,911.39). The difference in cost per responder between upadacitinib and dupilumab increased with higher EASI response levels.

Conclusion:: Considering five clinical endpoints, the cost per responder for upadacitinib 30 mg was always lower than for dupilumab 300 mg, highlighting its substantial clinical and economic benefits for patients with moderate-to-severe atopic dermatitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Paolo Gisondi received consultation fees for serving as a speaker in symposia for AbbVie, Almirall, Amgen, UCB, Jannsen, Novartis, Eli Lilly, Sanofi. Luca Stingeni is investigator and speaker for AbbVie, Almirall, Amgen, Leo Pharma, Lilly, Novartis, Pfizer, and Sanofi. Roberto Ravasio is a consultant of More Than Access S.r.l. Società Benefit and he has no conflict of interest in this research. Sara Di Fino, Anna Levi, Chiara Palladino and Gianluca Ronci are AbbVie employees and may own AbbVie stocks.

Figures

FIGURA 1 -
FIGURA 1 -
Costo per responder: EASI75 a 16 settimane.
FIGURA 2 -
FIGURA 2 -
Costo per responder: EASI90 a 16 settimane.
FIGURA 3 -
FIGURA 3 -
Costo per responder: EASI100 a 16 settimane.
FIGURA 4 -
FIGURA 4 -
Costo per responder: miglioramento WP-NRS ≥ 4 a 16 settimane.
FIGURA 5 -
FIGURA 5 -
Costo per responder: EASI90 & WP-NRS 0/1 a 16 settimane.
See this image and copyright information in PMC

References

    1. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: 10.1038/s41572-018-0001-z. - DOI - PubMed
    1. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–360. doi: 10.1016/S0140-6736(20)31286-1. - DOI - PubMed
    1. Drucker AM. Atopic dermatitis: burden of illness, quality of life, and associated complications. Allergy Asthma Proc. 2017;38(1):3–8. doi: 10.2500/aap.2017.38.4005. - DOI - PubMed
    1. Rønnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. J Am Acad Dermatol. 2018;79(3):448–456. e30. doi: 10.1016/j.jaad.2018.03.017. - DOI - PubMed
    1. Migliavaca CB, Lazzarini R, Stein C et al. Prevalence of Atopic Dermatitis: A Systematic Review and Meta-Analysis. Dermatitis. 2024 doi: 10.1089/derm.2024.0165. - DOI - PubMed

LinkOut - more resources